Live
FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, tooEndpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinicFierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract PharmaLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesEndpoints NewsParabilis Medicines charts $413M IPO to back peptide pipelineFierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADCPharmaVoiceHouse bill aims to crack down on China biotech dealsPharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problemsFierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
BioWorld 27 févr. 2026

Other news to note for Feb. 27, 2026

Other news to note for Feb. 27, 2026

Contenu indisponible. Consultez la source originale.